Annals of Gastroenterology最新文献

{"title":"Dietary supplement based on dihydromyricetin in metabolic dysfunction-associated steatotic liver disease: a double-blind, placebo-controlled, randomized clinical trial.","authors":"Εlisavet Michailidou, Stavros P Papadakos, Εleni Κoukoulioti, Sofia Paraskevopoulou, Maria Μela, Paraskevi Fytili, Panagiota Ioannidou, Εvangelos Cholongitas, Κonstantinos Τriantafyllou, George V Papatheodoridis","doi":"10.20524/aog.2026.1019","DOIUrl":"10.20524/aog.2026.1019","url":null,"abstract":"<p><strong>Background: </strong>Despite its increasing prevalence, effective treatment options for metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. We assessed the efficacy of a dietary supplement containing dihydromyricetin (DHM) in MASLD.</p><p><strong>Methods: </strong>Adult MASLD patients were randomized to receive a dietary supplement containing DHM (300 mg/day), vitamins C/E and choline (group A), or identical placebo (group B) for 12 months. Patients were assessed every ≤6 months for clinical and laboratory parameters and liver stiffness measurements (LSM).</p><p><strong>Results: </strong>Fifty-five patients were randomized to group A (n=28) or B (n=27), but 9 patients (group A/B=2/7) were withdrawn early for personal reasons. Median liver enzymes decreased at 6 or 12 months only in group A. Group A compared to B patients achieved higher 12-month rates of combined alanine aminotransferase (ALT)/γ-glutamyl transpeptidase (GGT) normalization (35% vs. 5%, P=0.028). Only in group A, glucose, glycated hemoglobin and total/low density lipoprotein mean levels had declined significantly at 6 and/or 12 months, whereas median liver stiffness measurements (LSM) were lower than baseline at both 6 and 12 months. In multivariate analysis, group A was the only factor associated with ALT/GGT normalization (P=0.038). Generalized estimating equation analysis revealed a significant treatment by time interaction for 12-month combined ALT/GGT normalization only in group A (P=0.021).</p><p><strong>Conclusions: </strong>The 6/12-month use of DHM supplement seems to result in improvements in liver enzymes and LSM, as well as in diabetes and lipid parameters in MASLD patients. Therefore, the use of such a supplement in MASLD needs further evaluation.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 1","pages":"54-62"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12850692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum anti-integrin αvβ6 autoantibodies for diagnosis of primary sclerosing cholangitis: a systematic review and meta-analysis.","authors":"Stavros P Papadakos, Stamatina Vogli, Alexandra Argyrou, Antonios Chatzigeorgiou, Andreas Koutsoumpas, Jiannis Vlachogiannakos, George V Papatheodoridis","doi":"10.20524/aog.2026.1025","DOIUrl":"10.20524/aog.2026.1025","url":null,"abstract":"<p><strong>Background: </strong>Currently, there is no noninvasive serological marker for primary sclerosing cholangitis (PSC). Serum anti-integrin αvβ6 autoantibodies were recently suggested as potential diagnostic PSC biomarkers. We conducted a systematic review and meta-analysis to evaluate their diagnostic performance, the influence of concomitant inflammatory bowel disease (IBD), and differentiation from other cholestatic liver diseases.</p><p><strong>Methods: </strong>PubMed, Embase, Cochrane Library and Web of Science databases were systematically searched for studies assessing the diagnostic value of serum anti-αvβ6 autoantibodies in PSC. Pooled sensitivity, specificity, diagnostic odds ratio and area under the summary receiver operating characteristic curve (AUC) were calculated using a bivariate random-effects model. Subgroup analyses were performed based on IBD status and differentiation from other cholestatic liver diseases.</p><p><strong>Results: </strong>Four studies including 1294 subjects (398 PSC patients and 896 controls) were analyzed. The pooled sensitivity and specificity of anti-αvβ6 autoantibodies for PSC diagnosis were 62.3% and 87.3%, respectively (AUC: 0.76). The specificity increased to 96% (AUC: 0.86) in PSC without IBD, while it decreased to 71% (AUC: 0.67) in PSC with IBD. For the differentiation of PSC from other cholestatic liver diseases, anti-αvβ6 autoantibodies had pooled sensitivity 81% and specificity 95% (AUC: 0.90).</p><p><strong>Conclusions: </strong>Serum anti-αvβ6 autoantibodies exhibit moderate sensitivity and high specificity for PSC diagnosis, especially in differentiation from other cholestatic diseases. Their clinical utility as a noninvasive diagnostic biomarker is promising and warrants validation in larger, multicenter prospective studies to establish their role in routine clinical practice.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 1","pages":"40-47"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12850684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of depression, anxiety and stress on self-care in inflammatory bowel disease: a systematic review.","authors":"Simone Amato, Alessio Lo Cascio, Francesca Iannuzzi, Michela Cocco, Nicoletta Orgiana, Antonio Maria D'Onofrio, Giovanni Camardese, Franco Scaldaferri, Marco Sguanci, Daniele Napolitano","doi":"10.20524/aog.2026.1024","DOIUrl":"10.20524/aog.2026.1024","url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, compromises both physical and psychological health. High levels of stress, anxiety, and depression are common yet often overlooked, negatively impacting treatment adherence and self-care. This review examines how psychological factors influence self-care behaviors in IBD and explores strategies to improve disease management. Following PRISMA guidelines and registered on PROSPERO (CRD42024575631), this systematic review applied the PICO model to identify studies involving IBD patients, self-care interventions, and outcomes related to depression, anxiety and stress. A comprehensive search was conducted in PubMed, CINAHL, Web of Science, Scopus, Cochrane Library, APA PsycInfo and Google Scholar (October-December 2024). JBI tools were used to assess risk of bias, and evidence was graded using the framework established by the Oxford Centre for Evidence-Based Medicine. Data extraction and synthesis were performed using structured tables and graphs. IBD patients frequently experience psychological distress that impairs self-care and quality of life. Depression is associated with low self-efficacy and maladaptive coping, while anxiety reduces treatment adherence, particularly in younger patients. Stress contributes to disease management difficulties, reinforcing the need for integrated psychological support. Psychological distress in IBD patients significantly affects self-care behaviors. Incorporating mental health support into standard care may enhance adherence, disease control, and overall well-being.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 1","pages":"11-22"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12850693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bezlotoxumab for prevention of <i>Clostridioides difficile</i> recurrence in patients with inflammatory bowel disease: a retrospective multicenter experience.","authors":"Christian Karime, Tarek Odah, Jana G Hashash, Darrell S Pardi, Sahil Khanna, Francis A Farraye","doi":"10.20524/aog.2026.1029","DOIUrl":"10.20524/aog.2026.1029","url":null,"abstract":"<p><strong>Background: </strong>Bezlotoxumab can reduce recurrent <i>Clostridioides difficile</i> infection (rCDI); however, data from patients with inflammatory bowel disease (IBD) are limited. Since rCDI is common in IBD, we assessed the efficacy of bezlotoxumab for rCDI prevention in patients with and without IBD.</p><p><strong>Methods: </strong>Adults who received bezlotoxumab for CDI were identified. Clinical variables and adverse events were collected during a minimum follow-up of 1 year. The primary outcome was rCDI, classified at 4 time intervals (30, 60, 90 days, and 1 year).</p><p><strong>Results: </strong>Of the 70 patients identified, 34 patients had IBD. Most patients (88.6%) had ≥2 prior CDI episodes (interquartile range [IQR] 1-4). Bezlotoxumab was commonly combined with vancomycin (61.4%) or fidaxomicin (42.9%), which did not differ between patients with and without IBD. Following bezlotoxumab, the 1-year rCDI rate was 28.6% (median 65 days, IQR 32.8-158.3), while the 30-, 60- and 90-day rCDI rates were 5.7%, 12.9% and 22.9%, respectively. Patients with IBD had comparable rCDI rates to non-IBD patients, including at 30 (5.9% vs. 5.6%, P>0.99), 60 (17.6% vs. 8.3%, P=0.30), and 90 days (20.6% vs. 13.9%, P=0.54), and 1 year (32.4% vs. 25.0%, P=0.60). A history of colorectal surgery or vancomycin exposure was more common among patients with IBD and rCDI. Adverse events occurred in 6 patients (8.6%), most commonly heart failure exacerbation.</p><p><strong>Conclusions: </strong>The rCDI rate following bezlotoxumab was similar in patients with and without IBD. In patients with IBD, a history of colorectal surgery or prior vancomycin exposure was more common among those who experienced rCDI.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 1","pages":"114-122"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12850694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of bipolar energy-based therapy for hemorrhoids: a systematic review.","authors":"Renuka Verma, Kyaw Min Tun, Kamleshun Ramphul, Banreet Singh Dhindsa, Douglas G Adler","doi":"10.20524/aog.2026.1022","DOIUrl":"10.20524/aog.2026.1022","url":null,"abstract":"<p><strong>Background: </strong>Hemorrhoids arise from dilated vessels in the submucosal layer of the anorectal canal. Hemorrhoids are responsible for 4 million office and emergency visits annually in the US. Hemorrhoidal energy therapy (HET) is a novel nonsurgical, bipolar energy-based instrument for treating hemorrhoids. It has multiple benefits, such as requiring only a single session for resolution of symptoms, and minimizing heat-related collateral damage. However, there are limited data regarding the effectiveness and adverse events of HET. We performed the first systematic review to evaluate the efficacy and safety of HET in the treatment of internal hemorrhoids.</p><p><strong>Methods: </strong>A comprehensive search was performed from major databases to identify studies that investigated HET to treat hemorrhoids. The primary outcomes were technical success and clinical success. The secondary outcomes were total adverse events and individual adverse events, such as postprocedural bleeding and incontinence.</p><p><strong>Results: </strong>Eight studies with 512 patients were included in the meta-analysis. The average age was 55.6 years, and the majority of patients were female. Most patients presented with grade I and grade II hemorrhoids. The HET demonstrated technical and clinical success rates of 100% and 86.1%, respectively. All adverse events were determined to be mild, according to the ASGE lexicon, except for 1 case of perianal hematoma that required hospitalization.</p><p><strong>Conclusion: </strong>Our study demonstrates that HET is an effective and safe treatment for grade I and II internal hemorrhoids.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 1","pages":"99-103"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12881760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146140599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single incision laparoscopic surgery for ileal J-pouch-anal anastomosis: a 15-year review of the literature.","authors":"Evangelia Balla, Dimitrios Dimitroulis, Nikolaos Garmpis, Ilektra Kyrochristou, Nikolaos Nikiteas, Dimitrios Patsouras","doi":"10.20524/aog.2026.1027","DOIUrl":"10.20524/aog.2026.1027","url":null,"abstract":"<p><p>Single-incision laparoscopic surgery (SILS) has emerged as a refinement of minimally invasive techniques, offering potential cosmetic and postoperative recovery benefits. This review aimed to evaluate the current evidence regarding the safety, feasibility, and outcomes of SILS for ileal J-pouch-anal anastomosis (IPAA). A structured literature search was performed in PubMed for studies published between January 2010 and January 2025, focusing on adult and pediatric patients undergoing restorative proctocolectomy with IPAA performed through a single incision. Twenty-two studies were identified, encompassing 182 procedures. The mean operative time ranged from 144-284 min. Reported conversion to multiport laparoscopy or open surgery occurred in 3.9% of cases, while the mean estimated blood loss varied from 27-136 mL. The median length of hospital stay was 4 days in most studies. Major postoperative complications (Clavien-Dindo grade ≥III) occurred in approximately 9% of patients, most commonly small-bowel obstruction or anastomotic leak. Cosmetic satisfaction and postoperative pain scores were generally favorable, although long-term functional outcomes were rarely reported. SILS-IPAA appears feasible and safe in selected patients, particularly when performed by experienced surgeons familiar with conventional laparoscopic restorative proctocolectomy. The current literature is heterogeneous and limited by small sample sizes and overlapping institutional data. Further comparative studies, especially in the context of robotic platforms, are needed to define the role of SILS in modern pouch surgery.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 1","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12850686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective international multisite randomized controlled trial of water exchange with and without distal cap(s) in adenoma detection.","authors":"Felix W Leung, Sergio Cadoni, Long Chen, Yu Chen, Chi-Liang Cheng, Ramsey Cheung, Vivek Dixit, David Elashoff, Shai Friedland, Paolo Gallittu, Yu-Hsi Hsieh, Chia Hsin Cheng, Noam Jacob, Nora Jamgotchian, Hui Jia, Yen-Lin Kuo, Bai-Ping Lee, Joseph W Leung, Donatella Mura, Jennifer Yi-Jiun Pan, Yanglin Pan, Susan Y Quan, Angshuman Saha, Aliya Shaikh, James Sul, Chih-Wei Tseng, Yi-Ning Tsui, Holly Wilhalme, Robert J Wong, Andrew W Yen, Linhui Zhang","doi":"10.20524/aog.2026.1020","DOIUrl":"10.20524/aog.2026.1020","url":null,"abstract":"<p><strong>Background: </strong>Interval cancers are linked to a low adenoma detection rate (ADR), prompting calls for benchmark-guided ADR performance improvement. Although water exchange and a straight cap (CAP) have been reported to independently improve ADR, the effects of Daisycuff^™ and Endocuff Vision^® remained unknown. We hypothesized that selected cap(s) could increase ADR and related water exchange outcomes.</p><p><strong>Methods: </strong>Subjects were randomized to No cap, or CAP, Daisycuff^™ and Endocuff Vision^® at 7, 5 and 2 sites. The primary outcome was ADR. Outcomes were compared for No cap vs. the above randomized caps.</p><p><strong>Results: </strong>Demographic and historic data revealed adequate randomization. Despite variations in site-specific pretrial ADR, the aggregated data showed that the ADR of No cap (45.6%) exceeded the latest benchmark (35%). Each added cap increased the ADR, and the difference using Daisycuff^™(52.8%) approached statistical significance (P=0.05). In the right colon, CAP and Daisycuff^™ significantly increased ADR. In the left colon, Daisycuff^™ significantly increased adenoma per colonoscopy. Factors that improved adenoma detection were consistent with published reports. Detection rates based on site, indication, sedation type, polyp size, shape and pathology in the No cap group were consistent with conventional data and were not influenced by the caps.</p><p><strong>Conclusions: </strong>The significantly higher right-colon ADRs with CAP and Daisycuff^™ suggest potential clinical relevance for reducing interval cancers. Although water exchange with or without caps yields ADRs that surpass the benchmark, the positive findings for selected cap(s) need to be confirmed in order to enhance the options for further improvement of water exchange.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 1","pages":"104-113"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12850690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune-mediated diarrhea and colitis with normal biochemical, endoscopic and histologic findings: a retrospective study.","authors":"Malek Shatila, Sharada Wali, Carolina Colli Cruz, Kei Takigawa, Andres Caleb Urias Rivera, Kian Abdul-Baki, Tanvi Gupta, Elliot Baerman, Linfeng Lu, Irene Jeong-Ah Lee, Raakhi Menon, Hamza Salim, Andrew Sullivan, Varun Vemulapalli, Cristina Natha, Ayesha Khan, Krishnavathana Varatharajalu, Stephane Champiat, Kerry L Reynolds, Lucy B Kennedy, Katy Tsai, Anusha Shirwaiker Thomas, Yinghong Wang","doi":"10.20524/aog.2026.1028","DOIUrl":"10.20524/aog.2026.1028","url":null,"abstract":"<p><strong>Background: </strong>Immune-mediated diarrhea and colitis (IMDC) due to checkpoint inhibition infrequently presents with normal stool biomarkers and no endoscopic or histologic evidence of inflammation. Little is known about the treatment needs and outcomes of this subset of patients. We aimed to describe this entity and clarify the role of immunosuppressive treatments in its management.</p><p><strong>Method: </strong>This was a single-center, retrospective study of patients treated with immune checkpoint inhibitors who developed clinical symptoms of IMDC, with no evidence of inflammation based on fecal calprotectin or endoscopic/histologic evaluation, between January 2010 and February 2024.</p><p><strong>Results: </strong>Of 1151 patients with IMDC, 131 (11.4%) had no evidence of inflammation. These patients more frequently had PD-1/L1 agent exposure (P=0.019) and presented with less severe diarrhea than patients with evidence of inflammation (P<0.001). This group had a lower rate of hospitalization (P=0.003). Around 40% of patients with no evidence of inflammation required immunosuppressive treatment. There was no difference in clinical symptoms or severity between patients requiring immunosuppression and those who did not.</p><p><strong>Conclusions: </strong>Our study is the first to explore IMDC with no elevations in calprotectin and normal endoscopic/histologic findings. We found that PD-1/PD-L1 inhibition may predispose patients to developing this form of IMDC, which is associated with a lower severity of diarrhea, fewer hospitalizations and lower recurrence rates. Many patients still require immunosuppressive treatment, and a small subset later develop colonic inflammation. Future studies are needed to further elucidate the treatment needs and outcomes of this patient population.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 1","pages":"79-87"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12850695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MUC1 as a biomarker in primary sclerosing cholangitis and cholangiocarcinoma.","authors":"Jana G Hashash, Pamela Beatty, Irene K Yan, Raouf Nakhleh, Micheal Camilleri, Denise Harnois, Francis A Farraye, Fadi F Francis","doi":"10.20524/aog.2026.1021","DOIUrl":"10.20524/aog.2026.1021","url":null,"abstract":"<p><strong>Background: </strong>MUC1 is a glycoprotein expressed at low levels in fully glycosylated form on healthy epithelial cells. In inflammation and malignancy, MUC1 becomes overexpressed and hypoglycosylated. We aimed to describe patterns of MUC1 expression in bile-duct tissue of patients with primary sclerosing cholangitis (PSC), PSC/cholangiocarcinoma, cholangiocarcinoma, and healthy controls.</p><p><strong>Methods: </strong>In this proof-of-concept pilot study, archived human liver tissue samples were identified and stained using anti-MUC1 antibodies. Staining for all MUC1, and specifically hypoglycosylated MUC1, was performed.</p><p><strong>Results: </strong>Tissue from controls minimally expressed the hypoglycosylated/abnormal MUC1. Tissue from patients with PSC demonstrated moderate expression. Very high levels were expressed in sporadic cholangiocarcinoma.</p><p><strong>Conclusion: </strong>MUC1 may serve as a biomarker in the identification of bile-duct disease and cancer.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 1","pages":"48-53"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12850687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for sedation-related adverse events during endoscopic ultrasound.","authors":"Patricia Abellán-Alfocea, Francisco Valverde-López, Juan Gabriel Martínez-Cara, Rita Jiménez-Rosales, Clara Heredia-Carrasco, Eduardo Redondo-Cerezo","doi":"10.20524/aog.2026.1018","DOIUrl":"10.20524/aog.2026.1018","url":null,"abstract":"<p><strong>Background: </strong>Complex endoscopic procedures such as endoscopic ultrasound (EUS) require higher doses of sedation, and thus carry a higher risk of adverse events compared to conventional endoscopy. This prospective cohort study assessed the safety of propofol sedation administered by non-anesthesiologists, and identified factors associated with sedation-related adverse events during EUS.</p><p><strong>Methods: </strong>A total of 2986 examinations were performed between January 2011 and May 2019. We collected data on patient characteristics (including age, body mass index and American Society of Anesthesiologists [ASA] class), procedural details, and sedation-related outcomes. Procedure characteristics and sedation-related adverse events were compared, firstly between interventional and diagnostic EUS, and then based on body mass index, ASA class and age. Logistic regression was performed to search for independent risk factors for sedation-related adverse events.</p><p><strong>Results: </strong>Sedation-related complications occurred in 4.8% of patients, hypoxemia being the most frequent (3.8%). Obese patients exhibited the highest rates of hypoxemia, early discontinuation and bag-mask ventilation (29.6%, 22.2% and 11.1%, respectively). Multivariate analysis revealed that obesity (odds ratio [OR] 8.57, 95% confidence interval [CI] 3.62-20.28) and comorbidities (ASA III/IV) (OR 2.04, 95%CI 1.44-3.01) were independently associated with sedation-related adverse events, while age was not significant.</p><p><strong>Conclusions: </strong>Propofol sedation administered by non-anesthesiologists during EUS was safe, with low rates of adverse events, the vast majority of which were clinically insignificant. Comorbidities and obesity, but not age, were independent risk factors for sedation-related complications during EUS. Appropriate patient selection and adequate training of endoscopists are warranted to minimize the risks associated with sedation during EUS.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"39 1","pages":"63-70"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12881761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146140595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}